Table 2 Risk factor of overall survival in advanced major salivary gland cancer patients, n = 395.
Crude HR (95% C.I.) | P-value | Adjusted HR (95% C.I.) | P-value | |
|---|---|---|---|---|
CRT vs RT | 0.90 (0.72–1.14) | 0.3771 | 0.94 (0.72–1.23) | 0.6654 |
Age | ||||
< 65 | Ref. | Ref. | ||
≧65 | 1.33 (1.01–1.75) | 0.0434 | 1.36 (1.01–1.83) | 0.0410 |
Gender | ||||
Male | 0.98 (0.78–1.23) | 0.8538 | 0.99 (0.78–1.26) | 0.9320 |
Female | Ref. | Ref. | ||
Grade | ||||
Well/moderately | Ref. | Ref. | ||
Poorly/undifferentiated | 1.15 (0.89–1.48) | 0.2912 | 1.14 (0.87–1.50) | 0.3296 |
Primary site criteria | ||||
Parotid gland | Ref. | Ref. | ||
Submandibular gland | 0.97 (0.74–1.27) | 0.8388 | 1.02 (0.76–1.36) | 0.9152 |
Sublingual gland | 1.19 (0.73–1.96) | 0.4830 | 1.38 (0.80–2.38) | 0.2511 |
Overlapping lesion of major salivary glands and major salivary gland, NOS | 1.02 (0.42–2.49) | 0.9578 | 1.01 (0.40–2.52) | 0.9850 |
Histological types | ||||
Adenoid cystic carcinoma | 0.87 (0.66–1.14) | 0.3013 | 0.79 (0.58–1.10) | 0.1622 |
Others | Ref. | Ref. | ||
pT classification | ||||
1–2 | Ref. | Ref. | ||
3–4 | 1.05 (0.78–1.41) | 0.7723 | 0.95 (0.66–1.36) | 0.7653 |
pN classification | ||||
0 | Ref. | Ref. | ||
1–3 | 0.90 (0.72–1.13) | 0.3565 | 0.84 (0.63–1.11) | 0.2204 |
Margin | ||||
Positive | 0.89 (0.70–1.13) | 0.3508 | 0.91 (0.70–1.18) | 0.4668 |
Negative | Ref. | Ref. | ||
CCI | ||||
0 | Ref. | Ref. | ||
1 | 0.78 (0.56–1.09) | 0.1493 | 0.77 (0.54–1.08) | 0.1308 |
≧2 | 0.89 (0.66–1.20) | 0.4353 | 0.84 (0.62–1.14) | 0.2635 |
